Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.3K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Humoral and Cellular Immune Response to the Administration of OrthopoxVac Vaccine to Volunteers.

Acta naturae·2025
Same author

An Attenuated and Highly Immunogenic Variant of the Vaccinia Virus.

Acta naturae·2024
Same author

Smallpox vaccination in a mouse model.

Vavilovskii zhurnal genetiki i selektsii·2023
Same author

Effect of the ati Gene Deletion on the Pathogenicity and Immunogenicity of the Vaccinia Virus.

Acta naturae·2023
Same author

Comparison of the Effectiveness of Transepidemal and Intradermal Immunization of Mice with the Vacinia Virus.

Acta naturae·2023
Same author

Genome stability of the vaccine strain VACΔ6.

Vavilovskii zhurnal genetiki i selektsii·2022
Same journal

The Microbiomic Metaproteome of the Taiga Tick Ixodes persulcatus from the Tyumen Region.

Acta naturae·2026
Same journal

The Distribution and Genetic Variability of Potato Viruses in Russian Regions.

Acta naturae·2026
Same journal

Stabilization of Transaminases in Aqueous-Organic Media by Pyridoxal-5'-phosphate: A Case Study of Transaminase from Desulfomonile tiedjei.

Acta naturae·2026
Same journal

Novel Nicotinic Acetylcholine Receptor Inhibitors Derived from Oleoylcholine Analogs.

Acta naturae·2026
Same journal

Identifying microRNA Expression Alterations in Erythrocytes, Lymphocytes, and Monocytes During Severe COVID-19.

Acta naturae·2026
Same journal

Cellular Type Is a Major Determinant of R-Loop Genomic Distribution.

Acta naturae·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

5.3K

Tumor Necrosis Factor Inhibitors.

T V Tregubchak1, S N Shchelkunov1

  • 1State Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk region, 630559 Russia.

Acta Naturae
|May 5, 2026
PubMed
Summary
This summary is machine-generated.

Novel therapies targeting tumor necrosis factor (TNF) are crucial for immune-mediated inflammatory diseases. This review explores new TNF inhibitors, including those from orthopoxvirus, to improve patient quality of life.

Keywords:
CrmBTNForthopoxvirusesrheumatoid arthritissmallpox

More Related Videos

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

8.2K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K

Related Experiment Videos

Last Updated: May 6, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

5.3K
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

8.2K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K

Area of Science:

  • Immunology
  • Inflammation
  • Drug Discovery

Background:

  • Immune-mediated inflammatory diseases (IMIDs) affect many globally.
  • Tumor necrosis factor (TNF) is a key driver in IMIDs like RA and Crohn's disease.
  • Current anti-TNF therapies face limitations in availability and cost.

Purpose of the Study:

  • To review recent advancements in developing novel TNF inhibitors.
  • To explore therapeutic potential of TNF inhibitors derived from orthopoxvirus.
  • To address the need for affordable and effective TNF-targeted treatments.

Main Methods:

  • Literature review of recent research on TNF inhibitors.
  • Analysis of immunomodulatory proteins from orthopoxvirus.
  • Evaluation of efficacy and safety profiles of emerging TNF inhibitors.

Main Results:

  • Several promising TNF inhibitors are under development.
  • Orthopoxvirus-derived proteins show potential as novel TNF inhibitors.
  • New strategies aim for improved efficacy and safety compared to existing therapies.

Conclusions:

  • Developing new TNF inhibitors is critical for managing IMIDs.
  • Orthopoxvirus-derived agents represent a promising avenue for novel therapies.
  • Further research is needed to bring these inhibitors to clinical practice.